SCHEMBL20416633

SCHEMBL20416633

CC(C)(Nc1cccc(CO[Si](C)(C)C(C)(C)C)n1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.37
MAPT P10636 1/20 0.37
PDE5A O76074 3/20 0.36
TACR1 P25103 1/20 0.34
PTGER2 P43116 3/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
BRD4 O60885 1/20 0.33
ITGB1 P05556 1/20 0.33
ITGA5 P08648 1/20 0.33
SHMT1 P34896 1/20 0.33
NR3C2 P08235 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
MEN1 O00255 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20416635 0.88 MEN1 (0.37) BACE1PDE5ATACR1IRAK4NR3C2
SCHEMBL4505482 0.85 PDE5A (0.42) BACE1PDE5ANR3C2CHRNB2CHRNB4
SCHEMBL20436541 0.83 BACE1 (0.34) BACE1PDE5AIRAK4
SCHEMBL20387967 0.80 NPC1 (0.41) BACE1PDE5ANR3C2CHRNB2CHRNB4
SCHEMBL28521553 0.80 APP (0.40) BACE1IRAK4ITGB1ITGA5ITGB3
SCHEMBL20416904 0.79 PTGER2 (0.39) BACE1PTGER2
SCHEMBL3530865 0.79 SMN1; SMN2 (0.40) BACE1MAPTPDE5ANR3C2CHRNB2
SCHEMBL11915102 0.79 BACE1 (0.33) BACE1IRAK4NR3C2
SCHEMBL20387979 0.78 HPGD (0.56) MEN1KMT2A
SCHEMBL20436539 0.77 CACNA1C (0.41) BACE1PTGER2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4310082-A2 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS Arcus Biosciences, Inc. (US) 2024-01-24 EP disclosed
WO-2018136700-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-07-26 WO disclosed